Strongbridge Biopharma plc (SBBP) relating to its proposed acquisition by Xeris Pharmaceuticals, Inc. Under the terms of the agreement, SBBP shareholders will receive 0.7840 shares of Xeris per share they own. SBBP shareholders will also receive one contingent value right, worth up to $1.00 in cash per share or equivalent Xeris stock upon achievement of certain triggering events.